Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GERSC for Breakthrough CINV in MEC/HEC Patients
NCT04085393Phase 2Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2020
- Primary completion
- Aug 2020
- Countries
- 1
01
Overview
A Phase 2 trial of granisetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by University of Alabama at Birmingham. Planned start Aug 2020; status: withdrawn.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT04085393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085393.